The concept of Structural Genomics (SG) arose towards the mid-1990s as a consequence of the availability of whole-genome information and the success of high-throughput (HTP) methods in DNA sequencing. It was envisaged that similar HTP methods could be applied to determining the 3-D structures of "all" the proteins (the "proteome") of an organism. As a part of a general research strategy for functional genomics, systematic, genome-driven and high-throughput crystal and NMR structure determination projects were planned. The rationale was that these data would significantly advance our understanding, at the
molecular, and eventually, at higher levels, of the functional processes underlying function and dysfunction of the cell and the organism. An interim objective was to provide an efficient way of filling existing gaps in "fold-space," i.e. to try to determine at least one structure for every existing sequence family, so as to provide suitable templates for modeling the structures of all the proteins present in a given genome. Till now, other gene products such as regulatory RNAs and ribozymes have remained outside the focus of SG projects.
Until quite recently, many structural biologists and protein chemists would have questioned the value of the use of homology modeling, in accurately predicting novel protein structures or for their use in drug design. But there are now an increasing number of examples where predicted structures have proved invaluable in both contexts, [1] [2] [3] and indeed in engineering proteins capable of performing novel functions. 4, 5 The SG "vision" led to the investment of very large sums of money in large scale projects, both in the USA (~$300 million invested by the NIH/NIGMS Protein Structure Initiative (PSI) in nine large centers from 2000 to 2005, 6 (http://www.nigms.nih.gov/psi), and in Japan (~US$70 million per annum invested in the Protein 3000 national project from 2002 to 2007, 7 with the bulk going to the RIKEN Research Institute, http://www.rsgi.riken.go.jp). Both these national programs were characterized by the concentration of large resources in a small number of big centers, by the concomitant development of novel, automated technologies for implementing a HTP pipeline approach to structure determination; a focus on novel folds as the major criterion for success; and for the US initiative, a policy requiring immediate public deposition of structural data.
In June 2005, the USA NIH/NIGMS activity moved into Phase 2, which involved the large-scale funding of four production units, and funding on a smaller scale of several other centers focussed on the development of complementary new technologies. Phase 2 will run through 2005-2010, again, with a total investment of ~$300M. investment, on a much smaller scale than the corresponding Japanese and US initiatives.
The worldwide activities briefly surveyed above led the SG/SP community to establish an organization called the International Structural Genomics Organization (ISGO), so as to exchange and coordinate views and information. ISGO is now a well-established body, which, among other activities, publishes, as its official journal, the Journal of Structural and Functional Genomics (JSFG), and organizes a biannual international SG conference.
The Differing Approaches of SG/SP and Classical Structural Biology (SB)
The strategy and implementation of the first SG projects launched in the USA were at the center of a major and thorough debate, 6 similar to that which preceded the funding and launching of the Human Genome Project a decade earlier. It was realized that implementation of SG programs required even more demanding technological developments than those required for the Human Genome Project. It was necessary to develop HTP procedures for a series of stages, from gene cloning through expression, protein purification, crystallization, data collection to structure analysis and refinement. It is a tribute to the efforts of the various SG projects taken together that automatized procedures have been developed for all these steps, although, hardly surprisingly, there is still much scope for improvement.
Although all the SG projects share the common objective of contributing to the "fold space," which will permit structural modeling of any protein with a known sequence, the individual SG consortia differ in the criteria for selecting their protein targets. Thus, for example, even within the framework of the US PSI initiative, some consortia chose family-based criteria for target selection, whereas others focussed on the genome of a given organism.
Much discussion was devoted to the productivity that might be expected from the various SG projects in terms of the number of structures determined. The first round of the PSI set a goal of determining about 10 000 structures. But it soon became clear that this initial goal was unrealistic; by the end of the first five years, ~1300 structures had been solved. The first round of the PSI was, however, successful in developing automatized technologies at a level that permitted the second round to enter into a "production" phase. It was also anticipated that, after an initial peak in generation of novel structures, a decline would occur after the easiest structures, the so-called 'low-hanging fruit,' had been determined. Moreover, to quote John Norvell, Director of the PSI at NIGMS/NIH, "… the fact remains that some proteins are not amenable to high-throughput approaches." Nevertheless, SG projects have already made, and are continuing to make, significant contributions to the determination of new folds and new domains, thus providing the various databases, such as CATH and SCOP, 9, 10 with a substantially larger number of unique new domains than had been provided by the standard structural biology (SB) approach. SG centers have indeed contributed to about half of the new SCOP families, superfamilies and folds in the two and a half years since January 1, 2004. Moreover, the structures solved by SG projects are ~4-fold less sequence-redundant than typical PDB structures.
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Extensive discussions were also directed towards the comparison between the approaches and impact of "SG/SP" versus "Structural Biology (SB)" endeavors. A significant proportion of the structures generated by SG/SP centers have lower citation levels than those generated by SB studies, 12 suggesting that the biological/functional characterization of a protein performed in the context of a classical SB study has a broader impact on the biochemical/biological community. Ultimately, however, the cumulative impact of SG/SP, by providing comprehensive structural data applicable to the majority of proteins, will most certainly excede the sum of the impacts of the individual structures solved. SG/SP projects aim to achieve as broad a coverage of the proteome as possible. As a consequence, target selection has, in general, been directed towards unique proteins, defined as proteins whose sequence has <30% identity with structures already present in the PDB. In contrast, a SB approach is usually devoted to the detailed study of a limited number of proteins, often already well characterized in terms of mechanism, specificity and biological role. This may result in the deliberate choice of a number of closely related proteins, or of complexes of a given protein with a number of ligands, in order to address in depth certain aspects of its mode of action and biological function.
It is now becoming apparent that the number of folds is quite limited, and that quite different sequences can assume a similar fold. 13 An awareness is also emerging that the classical SB approach and the SG/SP approach are, in fact, complementary, as the structure of a given protein is essential for understanding its function; but such an isolated snapshot does not suffice to provide complete functional knowledge.
Another major issue that has attracted the attention of the scientific community, and has promoted an ongoing debate, concerns both the size of the proteins studied and the quality of the structures determined, within the various SG/SP projects, as compared with the individual SB projects. Some scientists and officers of funding agencies had indeed expressed concern that, due to the HTP approaches adopted, the structures determined in SG/SP projects would be of lower quality than of those determined in the individual SB projects. It is widely accepted that the quality of the structures determined in the framework of SP/SG projects is quite comparable to, or even better than that of structures determined in SB projects. 14 If one compares the efforts of the PSI centers with those of traditional SB laboratories in terms of cost/structure, it has been calculated that novel structures solved by PSI centers are significantly less costly than those solved by traditional SB laboratories, whether the structures involved are individual novel structures per se, or new PFAM families or new SCOP superfamilies or folds. Futhermore, there is significant evidence that the cost for solution of structures at the PSI Centers is decreasing quite substantially. However, for large high-impact structures, like the ribosome, which contains a significant number of nonidentical polypeptide chains, this is not; in fact, the cost per individual polypeptide chains is significantly lower.
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The Goals and Policies of International SG/SP Projects
A compilation of the worldwide SG/SP initiatives, which updates progresses on the basis of the Target Registration Database (TB) of the PDB, 15, 16 is presented in Table 1 , which also lists the main focus of each project and its website. The first round of the PSI adopted an almost "pure" SG approach, which favored a high production rate for protein structures, and oriented target selection towards the principal goal of completing "fold space." This focus has been revised in PSI-II, where the focus has also been put on function in target selection, through the funding of specialized centers devoted to specific classes of proteins.
The PSI also invested major efforts, especially in PSI-1, in methodological developments essential for implementation of HTP approaches, and major technological advances were made as a consequence. These advances resulted in a dramatic reduction in the cost per structure. It has been estimated that the average cost per structure at the PSI centers, during the period from 1 February 2004 to 31 January 2005, was US$138 000.
PSI-2 is more oriented towards structure "production," exploiting the technical advances obtained during PSI-1. The total number of structures solved during PSI-1 (September 2000 to June 2005) was just over 1100 (http://www.nigms.nih.gov/ Initiatives/PSI/Background/PilotFacts.htm). During PSI-2, which is still ongoing, ~1200 structures have been solved so far, still far short of the 10 000 structures envisaged at the onset of PSI-1.
In Japan, the SG initiative at the RIKEN Institute focussed on the "fold" approach, i.e. aiming at the determination of the structures of a large number of distinct protein domains. To select the target proteins, mouse and plant genomes were clustered into families on the basis of amino acid sequences, and families for which no experimental structure was yet available were selected. Then, families of particular biological interest were prioritized. For protein production, the cellfree protein production method pioneered at RIKEN 17 has been used HTP methodology developments have also been carried out as a pilot project using a hyperthermophile. The consortium uses X-ray crystallography for structure determination.
(Continued ) Sciences, and the Shanghai Second Medical University. Five X-ray crystallography groups, three NMR groups, one bioinformatics group and four molecular biology/biochemistry groups are involved in these SG activities. The consortium is focusing on proteins expressed in human hematopoietic stem/progenitor cells, and on proteins related to blood diseases. 18, 19 In Taiwan, the new synchrotron-based Protein Crystallography Facility at the NSRRC was inaugurated in November 2005 (http://www.nsrrc.org.tw). With the NSRRC's protein crystallography beamlines having become operational, Taiwan is a new player in the fields of proteomics and structural genomics.
The Korean Structural Proteomics Research Organization was established in February 2002 to promote and coordinate proteomics research activities in Korea (http://xtalg.gist.ac.kr). Its major focus is on proteins of bacteria such as Mycobacterium tuberculosis and Helicobacter pylori, which may lead to discovery of new drugs for treatment of tuberculosis and ulcers, respectively. Both X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are being used for structure determination.
The Israel Structural Proteomics Center (ISPC) (http://www.weizmann.ac.il/ISPC) was established by scientists from the Weizmann Institute of Science, Rehovot, ISRAEL to increase the efficiency of all stages of 3D protein structure determination. 20 Targets submitted to the ISPC are primarily related to human health and disease. The center has a unique combination of scientific expertise and state-of-the-art instrumentation for high-throughput production and crystallization of proteins. Each target is cloned into multiple vectors, using ligation independent cloning. Expression is extensively screened in several bacterial strains with different fusion proteins. Proteins which are not soluble are expressed either in bacterial cell free extracts or in yeast (Pichia pastoris). Parallel purification of up to six proteins can be performed using an AKTA3D. Purified proteins are screened for crystallization using a Douglas Instruments ORYX6 robot, which employs the batch method under oil, and a TTP-Labtech MOSQUITO robot for sitting and hanging drops crystallization. This has yielded a highpercentage of high quality diffracting crystals. All the different stages are manipulated by a laboratory information management system (LIMS) in which several bioinformatics tools have been incorporated to facilitate the analysis of our targets. The ISPC now receives targets from scientists both in academia and industry. The ISPC believes that making structural information accessible to the entire scientific community will stimulate novel studies and developments related to health and disease.
The Taiwanese, Korean and Israeli projects show that even relatively small countries are capable of developing domestic SG/SP projects, evidence for the worldwide relevance and impact of the SG/SP endeavor.
In Australia, three SG projects are at the planning stage. They will focus on microbial virulence factors, macrophage proteins, and coldadapted organisms (http://www.isgo.org/list/index.php#Australia).
In addition to the SP/SG projects ongoing in the USA, Europe and Japan, transnational consortia are also being established. The most prominent, to date, is the Structural Genomics Consortium (SGC), headed by Aled Edwards, which was established in 2004, and maintains research centers in Toronto, Oxford and Stockholm. It focuses on human proteins of medical relevance, and is the first consortium to have solved the structures of a large number of human proteins, which are far harder to produce than prokaryotic proteins. 21 In order to coordinate the efforts of the multiple SG/SP projects currently functioning, the SG/SP community, in particular the publicly funded projects, have agreed on a series of actions directed towards making all the targets public, ensuring the prompt release of all structures analyzed, and facilitating the open exchange of new technologies as they come "on-line." A direct outcome of this policy has been the establishment of web sites and repository databases, which are providing the scientific community as a whole with open access to a wealth of data. Particularly relevant are the databases of selected targets, which allow researchers to avoid duplication in target selection (http://targetdb.pdb.org). This approach has indeed proved successful, as a recent survey 22 reported that only 14% of the structures determined by the various consortia have close homology (>30% sequence identity) with structures analyzed by other consortia. Databases containing information on methodological issues, such as cloning, expression, and purification, are also available. For example, the Protein Expression Cloning and Purification Database, PepcDB (http://pepcdb.pdb.org), was established to collect detailed status information and experimental details of each step in the protein production pipeline. 16 
Achievements of SG/SP Projects
The few years during which the various SG/SP projects have produced data and results can be used to measure their effectiveness and their impact. A simple way to measure their effectiveness is to count the number of experimentally determined structures that they have generated in terms of their absolute number, the fraction of the total structures deposited in the PDB, and, perhaps more importantly, the fraction of unique structures (defined as such on the basis of the sequence identity being <30% of that of any other structure deposited in the PDB).
In a recent paper, Chandonia and Brenner 12 reviewed the results and impact of SG efforts worldwide, and presented extensive statistics, with particular emphasis on structural novelty. Their analysis showed that the numbers of new structures or, more importantly, of the first structure reported for a PFAM family, came far more often from an SG/SP project than from a classical SB project. SG centers worldwide now account for about half of all new structurally characterized families. For PSI centers, for example, the percentage of domains representing a new SCOP fold or superfamily was 16%, significantly higher than for the non-SG average, which was 4%. For non-SG/SP structures, >70% of those solved in the past 10 years were related to proteins which had already been structurally characterized in a different state, i.e. with mutations, with bound ligands, or in a different complex. 12 The analysis of the achievements of SG projects and of the advancements in structural knowledge only in terms of the number of structures, of novel structures and reduced cost per structure is quite reductive. An additional major outcome has been the development of pioneering HTP technologies in the fields of protein production, purification and crystallization, as well as structure determination, using both X-rays and NMR. These achievements have fall-out well beyond the SG projects themselves, also contributing significantly to SB and to life science studies in general.
The structural knowledge provided by the SG/SP projects can suggest functional properties or a biological role for proteins of unknown function. Indeed, in a few cases, newly analyzed structures have been used to infer the functional properties and the mechanism of action of a given protein.
Finally, SG/SP projects, as a spin-off of their HTP approach, which involves screening for expression of several constructs of a number of orthologous genes for each of tens of thousands of targets worldwide, have produced huge archives of cloned and expressed proteins. The vast majority have not resulted in crystals suitable for X-ray data collection, or in samples suitable for NMR spectroscopy. Nevertheless, these archives contain a wealth of precious information for other biochemical and biological studies.
The European Structural Genomics Project SPINE
Europe, which tackled the SP/SG scientific challenge later than both the USA and Japan, has developed an approach combining features of both SP/SG and SB, and exploiting the positive aspects of the two disciplines. In particular, this has been the approach of SPINE, which was the first Structural Proteomics project to be funded at the European level.
SPINE developed an approach that combines technical and methodological development with the generation of protein structures of high medical relevance, selected from pathogens (as was done in the TB Structural Genomics Consortium (http://www.doe-mbi.ucla. edu/TB)) or from human proteins involved in diseases.
A principal contribution of SPINE has been to serve as a catalyst for the development of a pan-European network of laboratories with HTP SG/SP capabilities. SPINE has contributed to the spread of novel technologies (e.g. affordable nano-crystallization and expression screening robotics), rather than establishing large central facilities. It has taken advantage of the diversity of European laboratories so as to generate novel ideas or to benchmark alternative strategies, the best of which have then been more widely adopted.
SPINE has pushed the development of European standards in several areas of HTP technology, notably the development of LIMS systems and automatization of the handling of frozen crystals at synchrotrons (http://www.spineurope.org/page.php?page=protocol_ vials), which is already progressing towards courier mail transfer of crystals from the users to synchrotrons, and thus to monitoring of data collection by scientists from their home laboratories. Furthermore, it has been driven by the notion of selecting "highvalue targets for human health" rather than by "filling fold space" by solving many of the structures of an entire small proteome, or even by selecting "low-hanging fruit" in the context of development of techniques and methodologies. By so doing, it has provided a pragmatic working definition of the term "structural proteomics." Surprisingly, despite the fact that many of the targets selected by SPINE were difficult ones, the success rate that it has achieved in the structure determination of human proteins compares favorably with the success rates of other major SG programs focussed on bacterial proteins. Thus, the Joint Center for Structural Genomics (JCSG; http://www.jcsg.org), which started in 2000, is one of the most effective large US projects, and has focussed mainly on the proteome of the bacterial thermophile, Thermotoga maritima (with annual funding substantially greater than that allocated to SPINE). The scoreboard for this project, after seven years of operation, was (on 7/9/07): targets selected: 19 749; cloned: 16 213; expressed: 14 819; crystallized: 1082; solved: 465 (X-ray), 15 (NMR); deposited in PDB: 468. The corresponding output of SPINE after ~5 years operation is highly encouraging and on a par with the US projects: targets selected: 2395; cloned: 1534; expressed: 1177; soluble: 687; solved: 252 (X-ray), 56 (NMR); deposited in PDB: 122 (Jul, 2006). These figures also conceal considerable parallel work on many targets, with the total number of expression trials being ~14 000. The SPINE statistics, showing a total of 308 structures solved, reflect novel structures only; the number including ligand-and metal ionbound isoforms is >370, with more than 200 being human proteins. To put this in perspective, the total number of new human structures (with <95% identity to prior structures) deposited into the PDB during the first 11 months of 2005 was 337. It should be stressed, however, that the funding for structures that have been "counted" as SPINE targets, has not always been exclusively funded by SPINE only, as was the case for the PSI.
By its policy of maintaining an open decentralized network, together with a focus on high-value targets, SPINE has overcome the potentially divisive dichotomy between the "traditional" way of doing SB ("one post-doc/one project" with in-depth complementary functional investigations) and "factory-style" SG (multiple parallel projects, abandoning of failures, target proteins of often unknown function). The SPINE mode of work, whereby HTP techniques are exploited for high-value targets, is likely to become the norm for SB. SPINE has put in place strong links with a number of companies that have stimulated technology transfer to SMEs, and encouraged betatesting of new products in SPINE laboratories. Furthermore, the output of SPINE in terms of published papers is outstanding with, to date, 219 publications citing SPINE support.
The current and earlier SG/SP projects have revolutionized the way in which structural biology is now being done worldwide, through the introduction of novel automated, systematic and methodological strategies at each step of the structure determination pipeline (although their cost-effectiveness, particularly as a method for discovering new folds, is open to discussion). Of perhaps greater importance than the numbers of structures delivered, SPINE has had a remarkable impact in Europe, acting as the springboard for the second generation of FP6 Integrated Projects, such as VIZIER and BIOXHIT, which apply and further hone the appropriate technologies for specific target areas, as well as SPINE2-Complexes, initiated in the summer of 2006 (http://www.spine2.eu/index.php), which represents a step forward with respect to the classical, as one might say "old style" structural biology approach, as these new projects exploit a HTP "factory style" approach to address functional processes at the cellular level in their complexity and in their entirety. SPINE2-Complexes has moved on from the goals of SPINE, which were to advance technologies and solve structures of single proteins, to developing approaches for solving structures of protein complexes, with the eventual challenging objective of integrating such complexes into higher-order cellular structures. The measure of the success of the project will not be the number of structures solved but rather their biological impact.
The Scientific Advisory Board of SPINE, in their final review of its achievements during the three-year term for which it was funded, wrote to the European Commission as follows: "The SPINE impact on the European Community has been very significant and there is no other funding mechanism to accomplish what they have done. SPINE has been a tremendous success as the catalyst for structural biology throughout Europe. This model programme should be duplicated for other EU projects."
Highlights of SPINE'S Achievements
The following provides a snapshot of some of the major achievements of the SPINE project that have laid significant foundations on which future SG/SP research can build.
1. Efficient small-scale automated HTP pipelines for protein cloning, expression and purification in prokaryotes, now utilized by many European laboratories both within and outside SPINE.
2. New mammalian expression technologies and refinement of procedures for optimization of expression in eukaryotic systems. 3. Incorporation of quality assurance (QA) into the HTP protein production pipeline, including technologies such as mass spectrometry, ThermoFluor analysis and small-angle X-ray scattering. 4. Methods for achieving soluble expression of protein domains and subdomains, suitable for structural analysis, from previously intractable proteins. 5. Dissemination of nanoliter crystallization technologies. 6. Progress in crystal imaging and image recognition testing. 7. Development of 13 C protonless NMR spectroscopy methodology that provides a significant breakthrough in structure solution, particularly for larger proteins. 8. Establishment and testing of an expert system for crystal diffraction data collection from user laboratory to synchrotron; this involves utilization of automated procedures from sample loading through crystal alignment, to data collection and reporting. 9. Development of a SPINE sample holder standard has been adopted across Europe and, more recently, also in China (http://www.spineurope.org/page.php?page=protocol_vials). 10. An integrated protein information server for SG/SP, providing a comprehensive resource for protein selection, annotation and data collection: including PipeAlign, OPAL, OPTIC, FoldIndex, SeqAlert, SeqFacts, RONN, BestPrimers, OPINE, eHTPX hub, ISPyB, DNA automated data collection, ProFunc server, SURFNET, and many others. 11. Solution of the structures of 30 Bacillus anthracis structures out of 361 target proteins selected. 12. Analysis of more than 50 high-impact structures, including pathogen and human proteins (see http://www.spineurope.org). 13. Contributed to benchmarking definition in SG via a series of multi-lab comparisons of the various stages of expression and protein production. 14. SPINE played a major role in providing credibility for the consideration of structural biology as a research area whose requirements for infrastructure were eventually incorporated into the ESFRI Roadmap. This resulted in the funding of the preparatory phase of the new infrastructure INSTRUCT at the beginning of 2008.
The Legacy of SPINE
In large part due to large-scale EU support, SPINE has given visibility and identity to European scientists engaged in SP/SG, and has achieved an international stature comparable to that attained by equivalent large-scale projects in the USA and Japan. This provided an effective mechanism by which worldwide opportunities for scientific exchange in the field could be funnelled through SPINE to individual European laboratories. In a similar way, SPINE, and now SPINE2-COMPLEXES, due to the extensive network developed, can serve as a natural contact point for companies wishing to beta-test new technologies relevant to SG/SP, as positive results can be rapidly disseminated. SPINE has been exemplary in combining the expertise of the consortium members with that of related consortia, both inside and outside the EC, to pioneer benchmark procedures (e.g. for constructs, expression vectors, folding protocols, crystallization screens and their visual analysis, data collection and rapid structure determination), all of which may result in the adoption of pan-European standards. The establishment of such standards will be greatly facilitated through maintenance of careful quantitative records of both successes and failures, at all stages of the HTP pipeline, by means of the LIMS being built around the PIMS initiative, which arose largely out of preparatory work within SPINE. PIMS is destined to become a de facto standard in the area of SP/SG, for which such a standard is sorely lacking.
In parallel to work on structural analysis of the component proteins of the proteome, major efforts are now underway to map the interactions of human proteins (the so-called human "interactome"). This requires that the definition of human complexes be placed on a more systematic and complete basis, and European laboratories are playing an important role in this effort, building on the strong platform of achievement established by SPINE, and with the FP6 Integrated Project SPINE2-COMPLEXES positioned to play a leading role in this endeavor.
Other European Structural Genomics Projects 2002-2006
Following the success of SPINE, the EC funded a series of other programs in the area of SG/SP, focussing on specific SG/SP technologies, targets, standardization of methods, and plans for the future. The EC has several different instruments to fund projects, all of which require partners from at least three member countries (or associated countries, such as Switzerland and Israel). These programs, together with a brief summary of their activities, are listed in Table 2 .
Perspectives
The functional perspective is becoming increasingly relevant both to target selection and prioritization. Analysis of the entries in the PDB has shown that approximately 70% of the human genes with a Gene Ontology annotation (molecular function, biological process or cell component) are not yet structurally characterized by even one identifiable domain. The structural coverage of the human genome is even lower with respect to sequence space; there is approximately 10% coverage by structures with >40% sequence identity. 23 Indeed PDB content, not surprisingly, is significantly enriched in terms of functional coverage in "low-hanging fruit" and validated drug targets. Accordingly, SG projects are beginning to turn their attention from coverage of fold space to that of functional space. This includes individual proteins that are often hard to study, such as membrane proteins; however, attention is increasingly being turned to higher order structures, starting with functional complexes and the long term objective of obtaining structures of organelles and cellular structures. 
